Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

M. Boyd; S. Ross; J. Owens; D. Hunter; J. Babich; M. R. Zalutsky; T. G. Hamilton; S. Bell; R. J. Mairs

doi:10.2174/1570180043485743

ISSN: 1570-1808
E-ISSN: 1875-628X

Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene
Authors: M. Boyd¹, S. Ross², J. Owens³, D. Hunter⁴, J. Babich⁵, M. R. Zalutsky⁶, T. G. Hamilton⁷, S. Bell⁸ and R. J. Mairs⁹
View Affiliations Hide Affiliations

¹ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ² Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ³ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁴ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁵ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁶ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁷ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁸ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK. ⁹ Department of Radiation Oncology, Cancer Research UK Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, Scotland, UK.
Source: Letters in Drug Design & Discovery, Volume 1, Issue 1, Jan 2004, p. 50 - 57
DOI: https://doi.org/10.2174/1570180043485743
- Available online: 01 Jan 2004

Abstract

Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG (>104 GBq / mg) cured 100% of tumours.

Article metrics loading...

/content/journals/lddd/10.2174/1570180043485743

2004-01-01

2025-09-30

From This Site

/content/journals/lddd/10.2174/1570180043485743

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/content/journals/lddd/10.2174/1570180043485743

Article Type: Review Article

Keyword(s): gene therapy; mibg; noradrenaline transporter; targeted radiotherapy; xenograft

Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene

Abstract

From This Site

Most Read This Month

Most Cited Most Cited RSS feed

Discovery, Structural Determination and Anticancer Activities of Lactucinlike Guaianolides

Thermodynamic Aspects of Cancer: Possible Role of Negative Entropy in Tumor Growth, its Relation to Kinetic and Genetic Resistance

Immunomodulatory Properties of Synthetic Imidazolone Derivatives

Design and Prediction of ADME/Tox Properties of Novel Magnolol Derivatives as Anticancer Agents for NSCLC Using 3D-QSAR, Molecular Docking, MOLCAD and MM-GBSA Studies

Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease

Identifying Protein Binding Sites and Optimal Ligands

Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part I: Amides and Ureas

Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part II: Sulfonamides

Selection of a Catalytically Active Enzyme In Vivo Via Phage Display of its Product

A Comprehensive Review of the Advancement in Omic Technologies in the Field of Drug Discovery and Development